Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110591 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
A Phase 1 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00110591 is a Phase 1 study that has completed, run by CytoDyn. The registered enrollment target is 20 participants.
The verdict
NCT00110591, a Phase 1 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion. Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans and will result in measurable concentrations of the product in serum.
Interventions
- DRUG PRO 140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-04-16 |
| Est. Completion | 2008-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110591
The ClinicalTrials.gov registry entry for NCT00110591 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRO 140 is the first listed.
NCT00110591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110591 about?
NCT00110591 is a clinical study titled "Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers". The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion. Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans and will result in measurable concentrations of the pr...
What is the current status of trial NCT00110591?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2004-04-16. Estimated completion is 2008-03-31.
What interventions are being tested in trial NCT00110591?
The interventions under investigation include: PRO 140 (DRUG).
Who is sponsoring clinical trial NCT00110591?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.